OTCMKTS:ENDV Endonovo Therapeutics (ENDV) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 09/17/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About Endonovo Therapeutics Stock (OTCMKTS:ENDV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Endonovo Therapeutics alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0016Volume125,000 shsAverage Volume30.18 million shsMarket Capitalization$120.66 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Endonovo Therapeutics is a clinical‐stage biomedical company focused on developing non‐invasive therapeutic devices designed to modulate the immune system and promote tissue repair. The company’s proprietary Modulated Electrostatic Field (MEF) technology delivers pulsed energy to target inflammatory pathways and support cellular regeneration. Endonovo is primarily engaged in research and development aimed at treating conditions such as traumatic brain injury, hemorrhagic shock and acute inflammatory responses that currently have limited pharmaceutical options. At the core of Endonovo’s platform is a portfolio of portable devices that generate precisely calibrated electrostatic fields to influence cellular behavior and accelerate the body’s natural healing processes. Preclinical studies have demonstrated the company’s technology can reduce levels of proinflammatory cytokines, improve microvascular flow and enhance tissue viability following injury. Endonovo’s research pipeline encompasses multiple device configurations, each tailored to specific indications including central nervous system trauma and systemic shock scenarios. Operating as a US‐based medical technology developer, Endonovo Therapeutics maintains partnerships with academic institutions and contract research organizations to advance its clinical programs. While its headquarters and R&D activities are concentrated in North America, the company is exploring regulatory pathways overseas to extend its market reach. As it progresses toward human trials, Endonovo continues to strengthen its intellectual property portfolio, positioning its MEF platform for broader application across critical care and emergency medicine settings.AI Generated. May Contain Errors. Read More Receive ENDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENDV Stock News HeadlinesEndonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, IncMarch 28, 2024 | globenewswire.comEndonovo’s SofPulse® to Be Featured at Innovative Pain Management SolutionsMarch 4, 2024 | finance.yahoo.comRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.September 18 at 2:00 AM | Lear Capital (Ad)Endonovo's SofPulse® to Be Featured at Innovative Pain Management SolutionsMarch 4, 2024 | globenewswire.comEndonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 MillionDecember 4, 2023 | finance.yahoo.comEndonovo Therapeutics, Inc. (ENDV)November 21, 2023 | finance.yahoo.comLexeo Therapeutics Inc (LXEO)November 15, 2023 | investing.comEndonovo receives Taiwanese approval for SofPulse technologyOctober 13, 2023 | msn.comSee More Headlines ENDV Stock Analysis - Frequently Asked Questions How have ENDV shares performed this year? Endonovo Therapeutics' stock was trading at $0.0004 at the beginning of 2025. Since then, ENDV shares have decreased by 75.0% and is now trading at $0.0001. How do I buy shares of Endonovo Therapeutics? Shares of ENDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Endonovo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Novavax (NVAX), Energous (WATT), Advanced Micro Devices (AMD), BioLineRx (BLRX), Citigroup (C) and Ekso Bionics (EKSO). Company Calendar Today9/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolOTCMKTS:ENDV CIK1528172 Webwww.endonovo.com Phone(800) 489-4774Fax818-230-9899Employees1Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$10 thousand Price / Sales12.07 Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book0.00Miscellaneous Outstanding Shares1,206,610,000Free Float1,138,923,000Market Cap$120.66 thousand OptionableNot Optionable Beta-1.39 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:ENDV) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAmerica’s most terrifying chart?MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endonovo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Endonovo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.